R&D is
the heart of our mission to develop global medicines for incurable diseases.
Therapeutic Area | Project code | Indication | Discovery | Preclinical | Phase1 | Phase2 | Phase3 | BLA/NDA Review | Partners |
---|---|---|---|---|---|---|---|---|---|
Immunology | HL161 (batoclimab) | Myasthenia gravis (MG) |
US/EU |
![]() ![]() (China) |
|||||
Japan | |||||||||
China | |||||||||
Thyroid eye disease (TED) |
US/EU |
![]() (US/EU/Japan) ![]() (China) |
|||||||
Japan | |||||||||
China | |||||||||
Warm autoimmune hemolytic anemia (WAIHA) |
US/EU |
![]() (US/EU) |
|||||||
Neuromyelitis optica (NMOSD) |
China |
![]() (China) |
|||||||
Immune thrombocytopenia (ITP) |
China |
![]() (China) |
|||||||
Grave's Disease (GD) |
US/EU |
![]() (US/EU) |
|||||||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
US |
![]() (US/EU) |
|||||||
Oncology |
HL186 Anti-TIM3 Ab |
Immuno-oncology | US |
![]() |
|||||
HL187 Anti-TIGIT Ab |
Immuno-oncology | US |
![]() |
||||||
Ophthalmology |
HL036 (tanfanercept) |
Dry eye disease (DED) | US |
![]() ![]() |
|||||
China | |||||||||
HL189 (tanfanercept) |
Non-Infectious uveitis (NIU) | US | |||||||
Neurology |
HL192 (ATH399A) |
Parkinson’s Disease | US |
![]() ![]() |